Inoxgen

Nitric Oxide, the active ingredient in Inoxgen, is an inhaled nitric oxide presented as a gas for endotracheopulmonary use. It provides selective pulmonary vasodilation in patients with pulmonary hypertension, including newborns with persistent pulmonary hypertension and adults with acute respiratory distress. GNH USA supplies Inoxgen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, pharmacies and clinics worldwide.

Inoxgen is an inhaled nitric oxide used for selective pulmonary vasodilation in several critical care settings. - Persistent Pulmonary Hypertension of the Newborn (PPHN): reduces pulmonary artery pressure and improves oxygenation. - Acute Respiratory Distress Syndrome (ARDS) in adults: provides selective pulmonary vasodilation to enhance gas exchange. - Post‑cardiopulmonary Bypass Pulmonary Hypertension: lowers pulmonary vascular resistance to support hemodynamics.

Inoxgen may cause a range of adverse reactions that require monitoring.

Common Side Effects: - Methemoglobinemia: elevated methemoglobin levels reducing oxygen delivery. - Nitrogen dioxide formation: irritant gas that can damage lung tissue. - Transient hypotension: mild drop in systemic blood pressure. - Rebound pulmonary hypertension: increase in pulmonary pressure after abrupt discontinuation.

Serious or Rare Side Effects: - Severe hypotension: profound systemic blood pressure fall requiring intervention. - Pulmonary hemorrhage: bleeding within the lungs. - Acute kidney injury: renal function impairment in susceptible patients. - Neurological toxicity: seizures or altered mental status in rare cases.

Use of Inoxgen requires careful clinical oversight to minimize risks. - Methemoglobin monitoring: regularly check levels to detect methemoglobinemia early. - Anemia caution: avoid or adjust therapy in patients with severe anemia. - Renal/hepatic impairment: use with caution and consider dose adjustments. - Nitrogen dioxide control: ensure adequate ventilation and scavenging systems. - Gradual weaning: taper dose to prevent rebound pulmonary hypertension. - Store at ambient temperature: keep cylinder in original packaging, protect from heat and direct sunlight.

Inoxgen can interact with other agents that affect vascular tone or hemoglobin.

Major Interactions (Avoid): - Concurrent systemic pulmonary vasodilators (e.g., sildenafil, prostacyclin): may cause excessive hypotension. - High‑dose nitric oxide scavengers: can reduce therapeutic effect.

Moderate Interactions (Monitor Closely): - Inhaled anesthetics (e.g., sevoflurane): may potentiate vasodilatory response. - Blood transfusions or hemoglobin‑modifying agents: increase risk of methemoglobinemia. - Phosphodiesterase‑5 inhibitors: require blood pressure monitoring. - Anticoagulants: monitor for bleeding if pulmonary hemorrhage occurs.